Organ graft rejection is a T-cell-dependent process. The activation of alloreactive T cells requires stimulation of the T-cell receptor/CD3 complex by foreign major histocompatibility complex (MHC)-encoded gene products.
During an immune response, the initial activation of a quiescent T cell is mediated through the antigen-specific T-cell receptor (TCR) (1) . TCR activation occurs either through engagement of an antigenic peptide present in the antigenbinding groove of a self-encoded major histocompatibility complex (MHC) molecule or by engagement of a foreign MHC molecule (1) . However, several studies have demonstrated that signals transduced via the antigen receptor are not by themselves sufficient to lead to complete T-cell activation and proliferation but require a second costimulatory signal (2) (3) (4) (5) (6) (7) (8) . It has been hypothesized that this second signal(s) might be provided through one or more co-receptors on T cells interacting with their nonpolymorphic ligands on antigen-presenting cells (2, 9) . One candidate for this coreceptor activity is CD28, a 44-kDa polypeptide that is expressed on resting T cells as a homodimer. In vitro studies have demonstrated that CD28 is the surface receptor of a cyclosporin A-resistant T-cell signal transduction pathway (10) . Stimulation of CD28 by its natural ligand B7 provides costimulation to TCR-activated T cells, leading to proliferation and lymphokine gene expression (4, (11) (12) (13) (14) .
Unlike other T-cell co-receptors, CD28 is not colocalized or comodulated with the TCR, nor is CD28-mediated signal transduction dependent on TCR expression (15) (16) (17) . CD28 is encoded on human chromosome 2 (18) . Immediately adjacent to the CD28 gene is a closely related gene, CTLA-4, which shares 32% amino acid identity with CD28 and has a similar genomic organization (19) (20) (21) . Although CTLA-4 is not expressed on quiescent lymphoid cells and its physiologic role has yet to be defined, a recombinant fusion protein, CTLA4Ig, which contains the extracellular domain of human CTLA-4 fused to a human immunoglobulin Cy chain, was recently shown to specifically bind the CD28 ligand B7 with high affinity (Kd 12 nM) (22) . In vitro, CTLA41g blocks binding of CD28 to B7, and the only molecule that can be immunoprecipitated from 125I-labeled cell lines with CTLA4Ig is B7 (22) . In addition, CTLA4Ig blocks T-celldependent antibody production and inhibits the proliferation of activated T cells restimulated with allogeneic lymphoblastoid cell lines (22) . Although CTLA4Ig was constructed to contain the extracellular domain of the human CTLA4Ig gene, CTLA4Ig also binds efficiently to mouse and rat B7. In this report, we have used CTLA4Ig to examine the effect of blocking B7-induced T-cell activation on survival of cardiac allografts transplanted into fully MHC-mismatched rats.
MATERIALS AND METHODS
Monoclonal Antibody (mAb) and Reagents. Production of the fusion protein CTLA4Ig has been described (22) . L6 is a chimeric mAb that contains a murine variable region and a human Fc region (22) and was used as an isotype-matched control for CTLA41g. The mouse anti-rat mAbs R7.3 (anti-TCR) and OX-8 (anti-CD8) were purchased from Harlan (Indianapolis). mAb BWH-4 (anti-CD4) was a kind gift of C. B. Carpenter (Boston). Isotype-matched control antibodies were purchased from Coulter (Hialeah, FL), and fluorescein isothiocyanate-labeled goat anti-mouse mAbs were from Tago. Concanavalin A was purchased from Sigma and was used at 5 pug/ml. Animals Heart Allografting and Thymectomy. Heterotopic cardiac allografts were performed as described (24) . Briefly, the donor rats were anesthetized and mechanically ventilated, the right carotid artery was cannulated, and the heart/lung preparation was removed while being retrograde perfused. Next, the recipient rat was anesthetized and the donor heart was anastamosed to the carotid artery and the external jugular vein. After transplantation, heart transplants were assessed daily by palpation for mechanical function. When in doubt, graft function was independently assessed by electrocardiogram. Graft rejection was said to occur on the last day of palpable contractile function. When specified, recipient animals underwent thymectomy 3 days before heart transplantation.
Cell Staining and Flow Cytometry. Cells were stained with primary mouse anti-rat mAbs and counterstained with fluorescein isothiocyanate-conjugated goat anti-mouse antibody. Cells were analyzed on a FACScan (Becton Dickinson).
Cardiac Histology. After the animals were sacrificed, their hearts were excised and fixed in formalin. The fixed tissue was paraffin embedded, and tissue sections were stained with hematoxylin and eosin.
Determination of Serum CTLA4Ig Levels. The serum concentration of CTLA4Ig in treated animals was determined by binding to B7+ CHO cells as measured by flow cytometry (12) . CTLA4Ig concentrations were quantified by comparing the degree of binding with that of known concentrations of CTLA4Ig. The lower limit of detection by this assay is a serum level of =50 ng/ml.
RESULTS AND DISCUSSION
The effects of CTLA4Ig on the primary immune response to alloantigen were initially examined in a one-way mixed lymphocyte culture between Lewis rats (RT1', responder) and Norway rats (RT1n, stimulator) ( Fig. 1) . In this assay, a proliferative response will normally occur in 1-5% of cells as a result of activation through their cell-surface TCR in response to allogeneic MHC (25) . CTLA4Ig was able to block proliferation in a dose-dependent fashion with virtually complete inhibition observed at a concentration of 1 have been reported to be inhibited by nonstimulatory Fab' fragments of an anti-CD28 mAb (9) . Together, these data suggest that to mount a proliferative response in vitro, alloreactive T cells must be stimulated not only through MHC engagement of the TCR but also through costimulation of the CD28 receptor by B7 engagement.
CTLA4Ig was next used in a rat model of organ transplantation to ascertain its ability to block alloantigen responses in vivo. Recipient animals received a heterotopic cardiac allograft, which was anastamosed to vessels in the neck. Animals were treated with daily injections of CTLA4Ig or isotype-matched control mAb L6 for 7 days. This period of drug administration was selected because untreated Lewis rats reject heterotopic Norway rat allografts in 6.8 ± 0.3 days (n = 10). Therefore, as an initial test animals were treated until they were past the point at which rejection occurs in untreated animals. The allografts in CTLA4Ig-treated animals remained functional after completion of drug administration, whereas untreated animals, or animals treated with the L6 control antibody, uniformly rejected their grafts by day 8 (P < 0.0001) ( Table 1 ). CTLA4Ig-treated rats manifested no observable acute or chronic side effects from administration of the protein. No gross anatomic abnormalities were observed in CTLA4Ig-treated animals at autopsy. Pharmacokinetic studies initiated 24 hr after the administration of 0.5 mg of CTLA4Ig revealed a CTLA4Ig serum half-life of 2.8 days.
An untreated animal and a CTLA4Ig-treated animal were sacrificed on day 4 for histological examination of the allografts (Fig. 2) . The donor heart removed from the untreated animal showed histological findings of severe acute cellular rejection, including a prominent interstitial mononuclear cell infiltrate with edema formation, myocyte destruction, and infiltration of arteriolar walls. In contrast, the transplanted heart from the CTLA4Ig-treated animal revealed only a mild lymphoid infiltrate. Frank myocyte necrosis and evidence of arteriolar involvement were absent. The native heart from each animal showed no histological abnormalities.
To determine the duration of graft survival after CTLA4Ig treatment, animals treated for 7 days with daily injections of CTLA4Ig were observed without additional therapy until cessation of graft function. Graft survival was 18-40 days in animals treated with 0.05 mg of CTLA4Ig per day. This failure to induce permanent engraftment did not appear to be due to inadequate dosing of CTLA4Ig, as animals treated with a 10-fold higher dose (0.5 mg/day) showed a similar graft survival curve (Fig. 3) , with one animal maintaining longterm graft function (>50 days). Furthermore, serum CTLA4Ig levels during treatment in this group were in excess of 10 ,ug/ml, a concentration that is maximally suppressive in vitro (Fig. 1) . Serum measurements of CTLA4Ig fell below detectable levels by day 24. Histological examination of the CTLA41g (0.05 mg/day x 7 days; ---), isotype-matched control mAb L6 (0.5 mg/day x 7 days; ---), or no treatment (---) . In all cases, treatment was initiated at the time of transplantation. Graft survival was assessed daily and is displayed as the last day of graft function. Animals treated with a dose of 0.015 mg/day x 7 days have a mean survival of 13.2 + 2.5 days (n = 5).
The fact that 9 of 10 allograft recipients treated with the highest doses of CTLA4Ig (0.05-0.5 mg/day x 7 days) rejected their grafts within the study period indicated that blockade of the costimulatory molecule B7 for a finite period of time did not induce permanent graft acceptance. One potential explanation was that while CTLA4Ig treatment may have induced a state of nonresponsiveness in circulating T cells by allowing target antigen recognition without B7-dependent costimulation, newly matured T cells emerging from the thymus after cessation of CTLA4Ig treatment could mediate graft rejection as a result of B7-costimulated T-cell alloreactivity. To test this hypothesis, rats were thymectomized 3 days before cardiac transplantation and treated with daily injection of CTLA4Ig (0.5 mg/day x 7 days) after transplantation. These animals rejected their grafts between days 28 and 33 (n = 3), indicating that allograft recipients were not dependent on the influx of new T cells to initiate an alloimmune response. This suggests that CTLA4Ig-induced nonresponsiveness in host T cells may be only temporary. Alternatively, the kinetics of T-cell trafficking might not allow for all alloreactive cells to encounter donor antigens in the graft or in regional lymphoid tissue during the 7-day period of B7 blockade with CTLA4Ig. T cells that escaped this process could subsequently encounter graft antigens in the absence of B7 blockade and effect rejection.
Although CTLA4Ig blocks B7-dependent T-cell costimulation in vitro, it was important to verify that prolongation of cardiac allograft survival in vivo was not merely due to depletion of antigen-presenting cells from the allograft.
Therefore, 1 x 108 Norway rat spleen cells were injected intravenously into Lewis animals that simultaneously received 0.25-0.5 mg of CTLA4Ig. Control animals received spleen cells alone without CTLA4Ig. Fourteen days later, the animals received Norway rat heterotopic cardiac allografts without further immunosuppressive treatment. The 14-day delay between donor cell plus CTLA4Ig treatment and transplantation was chosen since, based on the pharmacokinetics of CTLA4Ig elimination, this is a time point at which serum levels are below the limit of detection. Graft survival in the control animals was 7-9 days (n = 3), whereas allografts in the CTLA4Ig-treated animals functioned for at least 15 days (n = 6) with two long-term survivors (>90 days). As an additional control, CTLA4Ig was administered alone at day -14 without accompanying donor cell transfusion. This protocol failed to prolong graft survival beyond 7 days.
We next examined the in vitro functional responses of lymphocytes from animals treated with donor-specific cell transfusion plus CTLA4Ig. Specifically, we wished to deter-mine whether these cells exhibited decreased antidonor reactivity and, if so, whether responses to third-party antigens remained intact. For these experiments, animals were sacrificed at day 7, a time at which all animals treated with this protocol exhibited normal graft function and control animals were uniformly undergoing rejection. When the mixed lymphocyte response of the treated animals was measured in comparison to control Lewis rats, a significant decrease in the response to Norway rat stimulators was observed-44,572 + 3584 (cpm; mean + SD; n = 3) versus 93,101 + 23,585 (P < 0.05). Both sets of animals responded equivalently to the third party stimulator Long-Evans, 9989 ± 2450 versus 10,865 ± 5610 (NS). These data suggest that CTLA4Ig-treated animals were specifically hyporesponsive to donor stimulators. However, in most animals this hyporesponsiveness was short lived as four of six animals treated in this manner rejected their transplanted heart within 31 days of transplantation. Even the two long-term survivors were not universally tolerant to Norway rat cells. Both animals rejected Norway rat skin within 3 weeks of skin grafting.
In all of our experiments, the immunosuppressive effect of CTLA4Ig lasted 2-6 weeks beyond the treatment period in most animals. This coupled with the failure of CTLA4Ig to induce permanent engraftments in thymectomized animals suggests that T cells present in the animals during the time of treatment are not rendered permanently tolerant. This finding is consistent with previous in vitro studies which have demonstrated that T-cell clones made tolerant by TCR activation in the absence of a costimulating signal can recover antigen-specific responsiveness if treated with interleukin 2 (3, 26, 27) . Nevertheless, the fact that deprivation of B7 costimulation at the time of exposure to alloantigen induces at least a temporary state of nonresponsiveness that is specific for donor antigens suggests that this may be a useful immunosuppressive strategy.
Several different approaches have been used to successfully suppress the immune response to allogeneic tissue grafts. These include depleting circulating T cells with toxins or antibodies (28), blocking TCR-mediated signal transduction with drugs such as cyclosporin A (29) , and interfering with the process of immune cell adhesion by using mAbs against leukocyte cell-surface molecules (30) . The use of B7 blockade with CTLA4Ig to prevent cardiac allograft rejection is likely to be a distinct immunosuppressive strategy for several reasons. First, because B7-dependent costimulation can be delivered independently of TCR stimulation (15) (16) (17) , it is unlikely that the effects of blocking cell-surface B7 are simply due to interfering with T-cell adhesion. Second, unlike TCR-mediated activation, the CD28 activation pathway is cyclosporin A resistant (10) . Third, the immunosuppression observed with CTLA4Ig did not result in significant alterations in circulating T-cell subsets. Finally, CTLA4Ig appears to act by blocking B7-dependent costimulation rather than by merely depleting the graft of B7+ antigen-presenting cells.
In conclusion, our data indicate that blockade of B7-dependent T-cell activation with a short course of CTLA4Ig administered at the time of transplantation can significantly prolong cardiac allograft survival. Thus, B7-dependent T-cell activation is required for acute cardiac allograft rejection. Strategies to induce more prolonged graft survival, such as continued deprivation ofcostimulation, use of CTLA4Ig with other immunosuppressive regimens, and donor-specific transfusion plus CTLA4Ig remain to be investigated.
Note Added in Proof. While this manuscript was in review, two manuscripts reaching similar conclusions were published (31, 32) .
